These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells. Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M. J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926 [Abstract] [Full Text] [Related]
23. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. Wang Q, Yu H, Ju DW, He L, Pan JP, Xia DJ, Zhang LH, Cao X. Gene Ther; 2001 Apr 15; 8(7):542-50. PubMed ID: 11319621 [Abstract] [Full Text] [Related]
24. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Tanaka F, Hashimoto W, Robbins PD, Lotze MT, Tahara H. Gene Ther; 2002 Nov 15; 9(21):1480-6. PubMed ID: 12378411 [Abstract] [Full Text] [Related]
25. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide. Cao X, Zhang W, Wan T, Yu Y, Tao Q, Wang J. J Exp Clin Cancer Res; 1999 Jun 15; 18(2):173-9. PubMed ID: 10464704 [Abstract] [Full Text] [Related]
26. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. O'Malley BW, Li D, McQuone SJ, Ralston R. Laryngoscope; 2005 Mar 15; 115(3):391-404. PubMed ID: 15744147 [Abstract] [Full Text] [Related]
27. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Ugai S, Shimozato O, Yu L, Wang YQ, Kawamura K, Yamamoto H, Yamaguchi T, Saisho H, Sakiyama S, Tagawa M. Cancer Gene Ther; 2003 Oct 15; 10(10):771-8. PubMed ID: 14502230 [Abstract] [Full Text] [Related]
29. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R. Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4538-46. PubMed ID: 17671140 [Abstract] [Full Text] [Related]
30. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity. Søndergaard H, Coquet JM, Uldrich AP, McLaughlin N, Godfrey DI, Sivakumar PV, Skak K, Smyth MJ. J Immunol; 2009 Dec 01; 183(11):7326-36. PubMed ID: 19915059 [Abstract] [Full Text] [Related]
31. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model. Chang CY, Lee J, Kim EY, Park HJ, Kwon CH, Joh JW, Kim SJ. BMC Cancer; 2007 May 23; 7():87. PubMed ID: 17519043 [Abstract] [Full Text] [Related]
32. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS. Exp Hematol; 2009 Oct 23; 37(10):1216-29. PubMed ID: 19638292 [Abstract] [Full Text] [Related]
33. Role of the endogenous production of interleukin 12 in immunotherapy. Harada M, Tamada K, Abe K, Yasumoto K, Kimura G, Nomoto K. Cancer Res; 1998 Jul 15; 58(14):3073-7. PubMed ID: 9679973 [Abstract] [Full Text] [Related]
34. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice. Lasek W, Golab J, Maśliński W, Switaj T, Bałkowiec EZ, Stokłosa T, Giermasz A, Malejczyk M, Jakóbisiak M. Eur Cytokine Netw; 1999 Sep 15; 10(3):345-56. PubMed ID: 10477391 [Abstract] [Full Text] [Related]
35. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses. Lee CH, Chiang YH, Chang SE, Chong CL, Cheng BM, Roffler SR. Clin Cancer Res; 2009 Apr 15; 15(8):2756-66. PubMed ID: 19318495 [Abstract] [Full Text] [Related]
36. Phenotypic and functional characteristics of in vivo-induced interleukin-12-activated killer cells. Nishimura T, Watanabe K, Lee U, Yahata T, Kobayashi M, Herrmann SH, Habu S. Immunol Lett; 1995 Dec 15; 48(3):167-74. PubMed ID: 8867847 [Abstract] [Full Text] [Related]
37. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. Sabel MS, Arora A, Su G, Mathiowitz E, Reineke JJ, Chang AE. Surgery; 2007 Nov 15; 142(5):749-60. PubMed ID: 17981196 [Abstract] [Full Text] [Related]
38. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice. Sun T, Kim TS, Waltz MR, Cohen EP. Cancer Gene Ther; 1995 Sep 15; 2(3):183-90. PubMed ID: 8528961 [Abstract] [Full Text] [Related]
39. Preliminary study on mouse interleukin-21 application in tumor gene therapy. Dou J, Chen G, Wang J, Zhao F, Chen J, Fang X, Tang Q, Chu L. Cell Mol Immunol; 2004 Dec 15; 1(6):461-6. PubMed ID: 16293216 [Abstract] [Full Text] [Related]
40. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M. J Immunol; 2009 Oct 15; 183(8):4904-12. PubMed ID: 19801515 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]